MONTREAL--(BUSINESS WIRE)--Feb. 19, 1998--AXCAN PHARMA(ME:AXP.) (TSE:AXP.) Axcan Pharma announced today that for the first quarter ended December 31, 1997, revenues more than doubled reaching $10,258,000 compared to $4,169,000 for the same period in the previous ...

MONTREAL--(BUSINESS WIRE)--Sept. 3, 1997--Axcan Pharma US Inc. (ME,TSE:AXP.), a wholly owned subsidiary of Axcan Pharma Inc., has completed the acquisition of the US rights to VIOKASE(R) an oral pancrelipase pancrelipase /pan·cre·li·pase/ (pan?kre-li´pas) a ...

MONTREAL--(BUSINESS WIRE)--Nov. 21, 1997--(ME:AXP.)(TSE:AXP.) Axcan Pharma Inc. announces an increase of 17 percent in total revenues to $20,072,000 for the year ended September 30, 1997, compared to the previous year's revenues of $17,099,000. The Company's net...

MARIETTA, Ga. -- Solvay Pharmaceuticals, Inc. today announced it has received an approvable letter from the U.S. Food and Drug Administration (FDA) with respect to its New Drug Application (NDA) for CREON([R]). CREON([R]) (pancrelipase delayed-release capsules, U...

MONTREAL--(BUSINESS WIRE)--Aug. 22, 1997--AXCAN PHARMA(TSE;ME AXP ) In announcing results for its third quarter ended June 30, 1997, Axcan Pharma Inc. indicated revenues of $4,662,000 compared to $4,220,000 for the corresponding period in the previous fiscal year. Th...

MONTREAL--(BUSINESS WIRE)--Sept. 3, 1997--(ME,TSE:AXP.) Axcan Pharma Inc. announces that it completed a transaction with Parke-Davis, a division of Warner-Lambert Company, for the acquisition by Axcan of all gastroenterology products previously marketed by Jouveinal ...

PED5 EDEMA, HYPOPROTEINEMIA, AND ACRODERMATITIS ENTEROPATHICA: AN UNCOMMON INITIAL PRESENTATION OF CYSTIC FIBROSIS. Antonio E. Muniz, MD, and Robin Foster, MD. Department of Emergency Medicine and Pediatrics, Medical College of Virginia of VCU, Richmond. Cysti...

Capsule Coating Fails QualityControl ...

Many patients with cystic fibrosis (CF) require large doses of enteric-coated pancreatic enzyme replacement therapy (EC-PERT) to achieve reasonable control of steatorrhea. One factor in CF that may contribute to a poor response to EC-PERT, and thus the need for higher...

BETHLEHEM, Pa., July 7 /PRNewswire/ -- Digestive Care, Inc. (DCI) announced today that it has submitted the first module of its New Drug Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the treatment of Exocrine Pancreatic Insufficiency ("...

The second part of this three-part series examines the safety of agents used to treat several gastrointestinal diseases that cause significant morbidity in pregnant women. ...

PHILADELPHIA -- Global Pharmaceuticals, the multisource products marketing division of IMPAX Laboratories Inc., currently markets 15 products, including terbutaline sulfate tablets (available exclusively from Global) and the full Lipram line of pancrelipase tablets...

PANCREATIC ENZYME TABLETS ...

MONTREAL--(BUSINESS WIRE)--Sept. 3, 1997--(ME,TSE:AXP.) Axcan Pharma Inc. announces that it completed a transaction with Parke-Davis, a division of Warner-Lambert Company, for the acquisition by Axcan of all gastroenterology products previously marketed by Jouveinal...

Simple, natural ways to stop it before it stops you. ...

GIVING MEDICATION TO YOUR TUBE-fed patient can be complicated. Why? Because feeding tubes often become obstructed during medication administration. ...